NEW YORK (GenomeWeb) – Albany Molecular Research (AMRI) announced it has obtained a non-exclusive license for CRISPR/Cas9 technology from the Broad Institute.
The contract research organization said in a statement that CRISPR offered "significant utility" for pharmaceutical research and development, especially drug target assessment, in vitro model development, and optimization. AMRI reported that it has already used CRISPR/Cas9 in both customer and internal R&D projects.
"The application of CRISPR-Cas9 technology benefits a number of the specific services that AMRI provides to its customers, including protein production, cell line and assay development, high content screening and analysis, and target validation and assessment," the firm said.
Financial and other terms of the agreement were not disclosed.
AMRI is the latest CRISPR/Cas9 licensing deal for the Broad Institute and the first since July, when Broad signed a CRISPR licensing deal with Evotech. Broad's foundational CRISPR/Cas9 patent is being challenged by the University of California in a patent interference proceeding; however, Broad has more than a dozen patents involving CRISPR.